Prestige Brands earnings
This article was originally published in The Tan Sheet
The weak cough/cold season and industry's voluntary removal of some pediatric cough/cold products contributed to a 1 percent drop in Prestige Brands Holdings' third-quarter revenues to $45.1 million compared to the prior-year period, the consumer products firm says Feb. 8. Prestige Brands also notes "competitive pressures on the Doctor's NightGuard dental protector" contributed to the decline. However, strong sales of the Murine brand and Clear Eyes helped soften the cough/cold revenue losses. Despite these problems, the company's overall third-quarter revenue is slightly ahead of the previous year's by $100,000 for a total of $80.2 million in the quarter...
You may also be interested in...
When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.
COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More
In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.